Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans

European Journal of Nutrition

Volumn 58, Issue 1, 2019, Pages 315-324

  Enhörning, Sofia ^a,b   Tasevska, Irina ^a,b   Roussel, Ronan ^c,d,e   Bouby, Nadine ^c,f   Persson, Margaretha ^a,b   Burri, Philippe ^b   Bankir, Lise ^c,f   Melander, Olle ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e BICHAT HOSPITAL   (France)

^f SORBONNE UNIVERSITÉ   (France)

Author keywords

Glucagon; Insulin; OGTT; Vasopressin; Water

Indexed keywords

ALBUMIN; COPEPTIN; CREATININE; GLUCAGON; GLUCOSE; INSULIN; POTASSIUM; SODIUM; UREA; BIOLOGICAL MARKER; GLYCOPEPTIDE; WATER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FLUID INTAKE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PLASMA OSMOLALITY; POTASSIUM BLOOD LEVEL; SODIUM BLOOD LEVEL; UREA BLOOD LEVEL; URINARY EXCRETION; URINE OSMOLALITY; URINE SAMPLING; URINE VOLUME; VASOPRESSIN BLOOD LEVEL; WATER LOADING; BLOOD; DOSE RESPONSE; DRINKING; METABOLISM; MIDDLE AGED; REFERENCE VALUE; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; FEMALE; GLUCAGON; GLYCOPEPTIDES; HUMANS; INSULIN; MALE; MIDDLE AGED; REFERENCE VALUES; WATER; YOUNG ADULT;

EID: 85038114965     PISSN: 14366207     EISSN: 14366215     Source Type: Journal    
DOI: 10.1007/s00394-017-1595-8     Document Type: Article

References (41)

1. Whitton PD, Rodrigues LM, Hems DA (1978) Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J 176:893–898
2. Keppens S, de Wulf H (1979) The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta 588:63–69
3. Abu-Basha EA, Yibchok-Anun S, Hsu WH (2002) Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51:1184–1190
4. Tanoue A, Ito S, Honda K, Oshikawa S, Kitagawa Y, Koshimizu TA, Mori T, Tsujimoto G (2004) The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Investig 113:302–309
5. Perraudin V, Delarue C, Lefebvre H, Contesse V, Kuhn JM, Vaudry H (1993) Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J Clin Endocrinol Metab 76:1522–1528
6. Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A (2012) Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 92:1813–1864
7. Baumann G, Dingman JF (1976) Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Investig 57:1109–1116
8. Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52:112–119
9. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J (2011) Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab 96:1046–1052
10. Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, Lantieri O, Balkau B, Bouby N, Bankir L, Bichet DG (2014) Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 99:4656–4663
11. Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, Groop L, Lyssenko V, Orho-Melander M, Newton-Cheh C, Melander O (2010) Plasma copeptin and the risk of diabetes mellitus. Circulation 121:2102–2108
12. Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, Bakker SJ (2012) Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 55:1963–1970
13. Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N (2015) Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab 100:3332–3339
14. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O (2011) Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 96:E1065–E1072
15. Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O (2013) Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes 37:598–603
16. Enhorning S, Hedblad B, Nilsson PM, Engstrom G, Melander O (2015) Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J 169:549–556 e541
17. Tasevska I, Enhorning S, Persson M, Nilsson PM, Melander O (2016) Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart 102:127–132
18. Velho G, El Boustany R, Lefevre G, Mohammedi K, Fumeron F, Potier L, Bankir L, Bouby N, Hadjadj S, Marre M, Roussel R (2016) Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes. Diabetes Care 39:2288–2295
19. Johnson EC, Munoz CX, Jimenez L, Le Bellego L, Kupchak BR, Kraemer WJ, Casa DJ, Maresh CM, Armstrong LE (2016) Hormonal and thirst modulated maintenance of fluid balance in young women with different levels of habitual fluid consumption. Nutrients 8: 302
20. Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, Hainault I, Enhorning S, Velho G, Roussel R, Bankir L, Melander O, Bouby N (2015) Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 58:1081–1090
21. Chan J, Knutsen SF, Blix GG, Lee JW, Fraser GE (2002) Water, other fluids, and fatal coronary heart disease: the Adventist Health Study. Am J Epidemiol 155:827–833
22. Dennis EA, Dengo AL, Comber DL, Flack KD, Savla J, Davy KP, Davy BM (2010) Water consumption increases weight loss during a hypocaloric diet intervention in middle-aged and older adults. Obesity 18:300–307
23. Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L, Group DESIRS. (2011) Low water intake and risk for new-onset hyperglycemia. Diabetes Care 34:2551–2554
24. Bouby N, Bachmann S, Bichet D, Bankir L (1990) Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 258:F973–F979
25. Strippoli GF, Craig JC, Rochtchina E, Flood VM, Wang JJ, Mitchell P (2011) Fluid and nutrient intake and risk of chronic kidney disease. Nephrology 16:326–334
26. Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, Salvadori M, Garg AX (2011) Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 6:2634–2641
27. Fedorowski A, Stavenow L, Hedblad B, Berglund G, Nilsson PM, Melander O (2010) Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). Eur Heart J 31:85–91
28. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B (2009) Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 94:123–129
29. Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, Fumeron F, Mohammedi K, Balkau B, Marre M, Bankir L, Velho G (2015) Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study. Am J Nephrol 42:107–114
30. Tasevska I, Enhorning S, Christensson A, Persson M, Nilsson PM, Melander O (2016) Increased levels of copeptin, a surrogate marker of arginine vasopressin, are associated with an increased risk of chronic kidney disease in a general population. Am J Nephrol 44:22–28
31. Jochberger S, Dorler J, Luckner G, Mayr VD, Wenzel V, Ulmer H, Morgenthaler NG, Hasibeder WR, Dunser MW (2009) The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med 37:476–482
32. Stoiser B, Mortl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG, Bergmann A, Pacher R (2006) Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Investig 36:771–778
33. Keller T, Tzikas S, Zeller T, Czyz E, Lillpopp L, Ojeda FM, Roth A, Bickel C, Baldus S, Sinning CR, Wild PS, Lubos E, Peetz D, Kunde J, Hartmann O, Bergmann A, Post F, Lackner KJ, Genth-Zotz S, Nicaud V, Tiret L, Munzel TF, Blankenberg S (2010) Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 55:2096–2106
34. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M (2007) Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 28:219–226
35. Roussel R, El Boustany R, Bouby N, Potier L, Fumeron F, Mohammedi K, Balkau B, Tichet J, Bankir L, Marre M, Velho G (2016) Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J Clin Endocrinol Metab 101:2432–2439
36. Cryer PE (2012) Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153:1039–1048
37. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB (1987) Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64:106–110
38. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053–4059
39. Ahren B (2009) Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes 58:726–731
40. Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N (2017) Acute and chronic hyperglycemic effects of vasopressin in normal rats, involvement of V1a receptors. Am J Physiol Endocrinol Metab 312:E127–E135
41. Bouby N, Ahloulay M, Nsegbe E, Dechaux M, Schmitt F, Bankir L (1996) Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 7:842–851